MedTrace Logo

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

NCT06740019 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-04

No results posted yet for this study

Summary

A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Conditions

  • Malignant Pleural Effusions (Mpe)

Interventions

DRUG

JMKX000197

for pleural perfusion

PROCEDURE

Tube thoracostomy drainage

Tube thoracostomy drainage

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Ning Li · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-28
Primary Completion
2025-12-31
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06740019 on ClinicalTrials.gov